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Preamble
The past year has brought many new concepts and an abundance of
new data on the nature, management, and outcome of heart failure.
The pace of change is accelerating. We look forward to an exciting
new decade of research. The prognosis of cardiovascular disease is
determined to a large extent by the ability to delay or prevent the de-
velopment and progression of heart failure.1 Accordingly, attention is
shifting to earlier diagnosis of and intervention for heart failure.
Patients with type-2 diabetes mellitus (T2DM)2 or coronary artery
disease (CAD)3 have a relatively good prognosis unless plasma con-
centrations of natriuretic peptides are increased, indicating important
cardiac or renal dysfunction. Adoption of a simple ‘Universal
Definition’ of heart failure based on natriuretic peptides would facili-
tate early diagnosis and treatment but lead to an enormous increase
in its prevalence and demand upon medical services.4 We need to
prepare for the impending shock.
Epidemiology and prevention
In cardiology, the term prevention is often used to mean delaying the
onset of disease; in other words, procrastination. Failure to appreci-
ate the difference between prevention and procrastination leads to
problems in projecting future healthcare needs and costs. Older peo-
ple have more co-morbid conditions that complicate management
but may also offer more opportunities for intervention; consequently,
more time and resources are required to manage older patients well.
A detailed report on heart failure in the UK shows that the median
age of onset has risen to about 80 years, consistent with improve-
ments in the treatment of hypertension and other risk factors for
atherosclerosis and better management of myocardial infarction.5
Unfortunately, data on left ventricular ejection fraction (LVEF) were
not available for this report. Analyses of the diagnostic pathway in pri-
mary care in the UK suggest that key investigations are often not
done.6–8 Similar data from other countries are urgently required.
Several large epidemiological surveys9,10 and analyses of large tri-
als11,12 have recently been published that allow the demographics,
aetiology, and management of heart failure to be compared
internationally.
Mineralocorticoid receptor antagonists (MRAs) are effective anti-
hypertensive agents that also improve the prognosis of patients with
heart failure and a reduced (HFrEF) and possibly preserved (HFpEF)
LVEF.13 Whether MRAs have specific effects on reducing other po-
tential drivers of the progression to heart failure such as inflammation
and fibrosis is currently under investigation.14,15
Genetic propensity to greater body fat was associated with the
risk of developing heart failure in an analysis on 367 703 UK Biobank
participants.16 However, the incidence of heart failure was only 1%
(4803 patients), the diagnostic criteria were not robust, and the in-
crease in risk was modest (odds ratio 1.22; 95% CI 1.06–1.41).
Further analyses on this population showed a strong relationship be-
tween cardio-respiratory fitness and grip strength and future inci-
dence of heart failure.17 A study of 4403 people considered for
bariatric surgery in Sweden and followed for 22 years, found that 188
(9%) of the 2003 who had surgery (25–35 kg weight loss; BMI 1 year
after surgery 32 kg/m2) developed heart failure compared with 266
(13%) of 2030 who did not (BMI after 1 year observation 40 kg/m2).18
Although these data suggest links between obesity and the risk of
developing heart failure, it is possible that obesity just provokes simi-
lar symptoms. Once heart failure has developed, obesity is associated
with a lower mortality, but this may also reflect earlier diagnosis
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..rather than a protective effect.19 Randomized controlled trials
(RCTs) of effective interventions for obesity are required to demon-
strate whether weight loss improves symptoms (likely) and clinical
outcomes (less certain).
A report from ‘the Atherosclerosis Risk in Communities’ (ARIC)
study confirmed the association between influenza epidemics and
hospitalizations for heart failure, reinforcing guideline-recommenda-
tions for vaccination20; an RCT is underway.21 Extended follow-up
(median 18.9 years) of the Women’s Health Initiative Hormone
Therapy trials, which randomized 27 347 women to various hor-
mone replacement regimens, showed that they had no effect on the
incidence of HFrEF or pEF.22
The ISCHEMIA trial (presented at the American Heart
Association 2019) compared strategies of early coronary revasculari-
zation, predominantly percutaneous, with conservative management
for stable CAD, some of whom had mild symptoms of heart failure
and/or a reduced LVEF. Revascularization did not reduce the risk of
myocardial infarction or death but increased the risk of stroke almost
four-fold and did not reduce new-onset heart failure over the follow-
ing 4 years.
Diagnosis
The Heart Failure Association of the European Society of Cardiology
has proposed a new scoring system for the diagnosis of HFpEF.23 Its
practical utility awaits confirmation.24 Simpler approaches may be
preferred.4
Congestion
Congestion lies at the heart of failure.25–27 Imaging has long been
used to identify dilation of the atria and venous system, which might
be termed haemodynamic congestion, for which natriuretic peptides
are a useful biomarker.25 More recently imaging has been used to
identify accumulation of fluid in tissues (tissue congestion),25,28–32
which may be associated with increases in the biomarker, (bio)-adre-
nomedullin.33 Imaging and biomarkers in combination are both sensi-
tive and specific for detecting a failing heart, a useful guide to the
severity of congestion and prognosis and a potential therapeutic tar-
get indicating successful management. Imaging remains the preferred
method for identifying the cause of heart failure. If congestion is cen-
tral to the management of heart failure, then better monitoring34 and
more effective (diuretic) interventions (perhaps acetazolamide?35)
should improve outcome (Take home figure).
Age and prognosis
Analysis of a large primary care database suggested that the cardio-
vascular (CV) prognosis of new-onset heart failure improved sub-
stantially between 2002 and 2014 [hazard ratio (HR): 0.73; 95% CI
0.68–0.80] for patients above and below the age of 80 years.5
However, in those aged >80 years, the fall in CV mortality was entire-
ly offset by non-CV mortality. In other words, treatment changed the
way that elderly patients died but not overall mortality (Figure 1).
Unfortunately, information on LVEF was not available; many patients
will have had HFpEF and, therefore, caution should be exercised in
Figure 1 Changes in cause-specific mortality and hospitalizations for patients with incident heart failure in the UK between 2002 and 2013.
Reproduced with permission from ref.5
2 J.G.F. Cleland et al.
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attributing the reduction in CV mortality to treatment of heart failure.
A systematic review of survey and registry data also suggested that
the prognosis of heart failure had improved; important determinants
of outcome were age and cardiology input to management.36 Frailty,
which might be considered a biological rather than chronological
measure of age, may be an even more powerful predictor of disability
and death.37
Guideline-recommendations for the treatment of HFrEF do not
discriminate by age. The Swedish Heart Failure Registry found that
prescription of ACE inhibitors or beta-blockers to patients with
HFrEF aged >80 years was associated with a lower mortality.38,39
However, observational associations have many explanations other
than a therapeutic effect.40 An individual patient-data meta-analysis of
three RCTs of MRA (RALES, EMPHASIS, and TOPCAT-Americas)13
suggested that MRAs exerted a similar reductions in mortality (by
about 25%) for patients with HFrEF above and below age 75 years
but benefit was less certain for HFpEF.
The diversity of heart failure
phenotypes
Precision-medicine, which should also be accurate, requires patients
to be classified in a way that informs management. For oncology, this
has focused on the genetic cause, tumour location, and spread. For
heart failure, a multi-system disorder, it is much more complex.41–47
Current, therapeutically relevant classifications of heart failure in-
clude the severity of congestion (based on symptoms, signs, blood bio-
markers, and imaging), CAD, heart rate and rhythm and QRS duration,
blood pressure, serum potassium, renal function, indices of iron defi-
ciency, mitral regurgitation, infiltrative myocardial disease (e.g. amyloid),
and ventricular phenotype.41,48 Optimal management of heart failure,
with a few rare exceptions, requires only a modest amount of informa-
tion but this still creates many thousands of patient-subgroups or clus-
ters that might have different therapeutic needs.45,46 Such subgroups
will increase exponentially with the introduction of each new class of
treatment. Despite this heterogeneity of substrate and wealth of inter-
ventions, precision-medicine is in its infancy in heart failure.
One therapeutically relevant classification of heart failure is by
LVEF, a surrogate for left ventricular (LV) dilation. Prior to the 1980s,
imaging of cardiac function was available only in expert centres.
Clinical trials relied on the chest X-ray rather than the echocardio-
gram to support a diagnosis of heart failure. The success of trials such
as SOLVD, MERIT, and CHARM, which all had a reduced LVEF as an
inclusion criterion, led to the adoption of LVEF <40% as the
European Society of Cardiology (ESC) Guideline definition for
HFrEF.49 Values >_40% were termed HFpEF, comprising patients with
a mid-range or mildly-reduced (HFmrEF), normal (HFnEF) and, per-
haps, supra-normal (HFsnEF) LVEF.50 Analyses of >350 000 routinely
collected echocardiograms suggested that the nadir of risk, whether
or not the patient has a diagnosis of heart failure, lies in the range 60–
65% both for men and women. Interestingly, an LVEF of >70% was
associated with similar risk as an LVEF of 30–40% (Figure 2).50
The ESC Guidelines of 2016 introduced the concept of HFmrEF,
for two main reasons. Firstly, because of imprecision, an echocardio-
graphic measurement could not reliably distinguish between
two measurements of LVEF within 10% of each other. Creating a
buffer-zone between HFrEF and HFnEF meant that misclassification
was less likely. This innovation meant that a trial of HFpEF could not
claim benefit for all patients with an LVEF >40% based solely on an ef-
fect in those with an LVEF 40–49%. Secondly, the introduction of
HFmrEF challenged the convention that an LVEF <40% was the cor-
rect threshold for HFrEF. Some analyses subsequent to the ESC
2016 Guideline suggest that patients with an LVEF <50% may re-
spond to treatment similarly to those with an LVEF <40%.51
However, this interpretation could reflect confirmation-bias amongst
enthusiastic proponents of HFmrEF (Table 1). The evidence is not so
consistent when looked at in its entirety, especially if mortality is con-
sidered a key outcome. In the future, many trials will probably include
both HFrEF and HFmrEF, others will include HFmrEF, HFnEF, and
HFsnEF, but NT-proBNP should be used routinely to stratify risk and
potentially exclude low-risk patients who have little to gain from yet
another ‘pill’. Assuming we continue to use LVEF to classify patients,
which seems likely since we cannot undo the past, then the major
issue is where to set thresholds. For HFrEF, these have ranged from
<25% in COPERNICUS, <30% in MADIT-II, and RAFT to <35–40%
for the bulk of other trials.51 For HFpEF, LVEF has generally been set
at >40% or >45% with no upper limit. Analyses of recent trials have
led some to suggest that, for patients with an elevated NT-proBNP,
the upper limit of LVEF for HFmrEF should be increased to 55% or
even 60% but this seems premature until consistency is demon-
strated across multiple interventions and end-points and measure-
ment precision for LVEF improves.
In a substantial observational study of patients with HFpEF and pul-
monary hypertension, progression of right rather than left ventricular
Figure 2 All-cause mortality according to left ventricular ejection
fraction reported on >350 000 routine echocardiograms stratified
by age and sex. HFmrEF, heart failure with mildly reduced ejection
fraction; HFnEF, heart failure with normal ejection fraction; HFrEF,
heart failure with reduced ejection fraction; HFsnEF, heart failure
with supra-normal ejection fraction. Reproduced with permission
from ref.50
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..dysfunction was observed and was associated with an increased risk
of atrial fibrillation (AF) and death.52 Although right ventricular (RV)
dysfunction is a powerful prognostic marker, remarkably few trials
focusing on RV dysfunction have been done (SERENADE: https://clini
caltrials.gov/ct2/show/NCT03153111).
Atrial fibrillation
About a third of outpatients, perhaps more for those with HFpEF,53
and more than half of those admitted with heart failure will be in AF,
which is associated with an adverse prognosis even after correcting
for age and other risk factors.54 Controversy continues over whether
medical management focused on rate control or restoration of sinus
rhythm is the better strategy for AF and heart failure. In practice, the
strategy needs to be tailored to the patient. When AF is the driver of
symptoms and worsening cardiac function, restoration of sinus
rhythm might be appropriate but when AF reflects the progression of
underlying cardiac dysfunction, it may not.55 For new-onset or parox-
ysmal AF associated with a clear deterioration in symptoms, restor-
ation of sinus rhythm may be warranted to improve symptoms. For
long-standing AF and heart failure with markedly dilated atria, sus-
tained restoration of sinus rhythm and atrial contraction is less likely.
Optimal pharmacological management includes anticoagulation,
avoiding toxic anti-arrhythmic agents and lenient ventricular rate con-
trol. Beta-blockers are the agent of choice for rate control, a resting
day-time ventricular rate of 70–90 b.p.m. is preferred,49 which may re-
quire only modest doses; digoxin should be used sparingly, if at all.
Unfortunately, RCTs of rate vs. rhythm control for AF have failed to
optimize the rate control strategy in the above fashion.
A meta-analysis of RCTs of rate vs. rhythm control included four tri-
als (n= 2486) comparing pharmacological rhythm to rate control found
no difference in mortality or thromboembolic events but an increase in
hospitalizations, often due to recurrent AF, in the rhythm control
group.56 Six trials (n= 1112) comparing AF ablation with rate control
reported reductions in mortality (0.51; 95% CI 0.36–0.74), hospitaliza-
tions (0.44; 95% CI 0.26–0.76), and stroke (0.59: 95% CI 0.23–1.51) and
an improved quality of life.56 However, none of the trials individually
had a robust result, patients were highly selected and the rate control
strategy was not optimal. As such, this meta-analysis should be consid-
ered hypothesis generating. Further trials are required with greater in-
volvement of heart failure physicians.
Implanted electrical devices
The controversy over the role of high-energy devices for heart failure
continues. Long-term follow-up of cardiac resynchronization therapy
....................................................................................................................................................................................................................
Table 1 Evidence supporting or refuting the benefits of treatments for heart failure with a left ventricular ejection
fraction in the “mid-range” (HFmrEF: 40–49%)
LVEF Symptoms Hospitalization
for heart failurea
CV death or HFHa CV mortality All-cause mortality
Diuretics
Perindopril Improved 0.38 (0.19–0.75)b
Candesartan Improved 0.72 (0.55–0.95)
Q
0.76 (0.61–0.96) 0.81 (0.60–1.11) 0.79 (0.60–1.04)
Irbesartan 0.98 (0.85–1.12)D
ARNI (Sac/Val) vs. Valc Improved 0.77 (0.58–1.02) 0.81 (0.64–1.03) 0.94 (0.69–1.28) NYR
MRA (overall)c 0.76 (0.46–1.27) 0.72 (0.50–1.05) 0.69 (0.43–1.12) 0.73 (0.49–1.10)
MRA (Americas)c 0.60 (0.32–1.10) 0.55 (0.33–0.91) 0.46 (0.23–0.94) 0.58 (0.34–0.99)
ß-Blocker (SR) Improved 0.95 (0.68–1.32) 0.83 (0.60–1.13) 0.48 (0.24–0.97) 0.59 (0.34–1.03)
ß-Blocker (AF) Improved 1.15 (0.57–2.32) 1.06 (0.58–1.94) 0.86 (0.36–2.03) 1.30 (0.63–2.67)
Ivabradine
Digoxin 0.80 (0.63–1.03) 0.96 (0.79–1.17) 1.24 (0.94–1.64) 1.08 (0.85–1.37)
Rivaroxaban vs. aspirin 0.65 (0.40–1.05) 0.75 (0.53–1.06)
RivaroxabanþAspirin vs. aspirin 0.87 (0.56–1.35) 0.63 (0.44–0.90)
CRT
ICD
BNP-guided therapy Reduction from 67% to
44% patients with an event
Statistically significant results are shown in bold on a blue background. Blank cells indicate no relevant information reported. Other data shown are not significant, although may
not be heterogeneous with the effect in patients with a reduced left ventricular ejection fraction (HFrEF). Data for sacubitril/valsartan taken from reference for LVEF >42.5% to
52.5%.98
AF, atrial fibrillation; ARNI, angiotensin receptor-neprilysin inhibitors; BNP, brain natriuretic peptide; CRT, cardiac resynchronization therapy; ICD, implantable cardioverter de-
fibrillator; LVEF, left ventricular ejection fraction; MRA, Mineralocorticoid receptor antagonist; SR, sinus rhythm.
aRecurrent event analyses used when available.
bThe PEP-CHF trial specified inclusion of patients with LVEF 40–49% as was LVEF >49% but did not report effects in this subgroup. However, it did report effects in patients
with a prior myocardial infarction who were more likely to have HFmrEF.
cStronger effect in women.
4 J.G.F. Cleland et al.
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..(CRT) in a French Registry showed a low rate of sudden death
amongst patients who received CRT-Pacing (without a defibrilla-
tor).57–59 A systematic review of observational studies and RCTs
reported that differences in the rate of sudden death with CRT-
Pacing and CRT-D were narrowing.58 RCTs comparing CRT-Pacing
and CRT-D are underway59 (Take home figure). Whether myocardial
scar found on cardiac magnetic resonance imaging identifies patients
with more to gain from an implantable cardioverter defibrillator
(ICD) is also under investigation60 (CMR_GUIDE; https://clinical
trials.gov/ct2/show/NCT01918215). Retrospective analysis of SCD-
HeFT found that patients with T2DM did not benefit from an ICD.61
An individual patient-data meta-analysis confirmed a reduction in sud-
den death with MRA.62 A systematic review identified 22 studies with
post-mortem interrogation of ICDs; the analysis suggested that 24%
of sudden deaths were not arrhythmic.63 A substantial multi-point
pacing trial failed, so far, to show improvements in the clinical or
echocardiographic response to CRT.64
Mitral regurgitation
COAPT suggested that a percutaneously delivered mitral clip could
reduce functional (secondary) regurgitation with a subsequent sub-
stantial improvement in morbidity and mortality that was moderately
cost-effective in a US healthcare context (US$40 361 per life-year
gained and $55 600 per quality-adjusted life year).65–68 Two-year fol-
low-up of MITRA.fr suggested no benefit.69 A possible explanation
for the apparent discrepancy could be the ratio of the severity of LV
dysfunction to the severity of mitral regurgitation. When regurgita-
tion is disproportionate to the severity of LV dysfunction it may drive
disease progression and correction may improve outcome.70,71
When regurgitation is proportionate to the severity of LV dysfunc-
tion, fixing the mitral regurgitation may be less useful because myo-
cardial dysfunction drives disease progression. The concept is simple
and plausible but application in practice may be difficult. Mitral regur-
gitation offloads the LV and may mask dysfunction. It is also likely that
there is a spectrum of primary and secondary mitral regurgitation,
with some patients having a mixed picture. More experience and fur-
ther data from RCTs may improve patient selection (RESHAPE-HF2:
https://clinicaltrials.gov/ct2/show/NCT02444338). However, opti-
mizing guideline-recommended therapy, including diuretic dose, may
cause mitral regurgitation secondary to dilation of the LV and mitral
ring to improve or resolve. Other technologies for secondary mi-
tral72 and tricuspid regurgitation73,74 are being developed.
Coronary artery disease
In COMPASS (n= 27 395), 5902 with CAD, in sinus rhythm and with
a diagnosis of heart failure (predominantly HFpEF) were randomly
assigned them to aspirin 100 mg/day, rivaroxaban 5 mg bd or aspirin
and rivaroxaban 2.5 mg bd.75,76 The study was stopped early for
benefit on the primary endpoint (a composite of CV death, stroke, or
myocardial infarction) with the combination compared with aspirin
alone. Further analysis suggested a reduction in all-cause mortality for
patients with heart failure, especially HFpEF, assigned to combination
therapy (HR: 0.63; 0.44–0.90) or rivaroxaban alone (HR: 0.75; 0.53–
1.06) with an estimated 4% absolute difference at 2 years; rather simi-
lar to the magnitude of effect in HFrEF for sacubitril-valsartan77 or
dapagliflozin78 (Figure 3). This suggests that coronary events might be
Take home figure Two-year cause-specific mortality and non-fatal vascular events for patients with cardiovascular disease according to New
York Heart Association (NYHA) class. Numbers and proportions are a conceptual representation of absolute and relative risk and are not strictly
evidence-based. Note that for patients in NYHA Class 4, interventions for sudden arrhythmic death may be ineffective or fail to lead to a meaningful
prolongation of life because the patient is likely soon to die of worsening heart failure. CRD, congestion-related death, otherwise called death due to
worsening heart failure; NFVE, non-fatal vascular event (e.g. myocardial infarction and stroke; note that events are more likely to be suddenly fatal as
heart failure progresses); non-CVD, non-cardiovascular death; RSAD, resuscitatable sudden arrhythmic death; SVD, sudden vascular death; TSAD,
terminal (non-resucitatable) sudden arrhythmic death. Reproduced with permission from ref.59
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..an important driver of death in HFpEF (Take home figure), although
effects of rivaroxaban on endothelial function, inflammation, and fi-
brosis should not be discounted. The analysis also suggests that those
who do not have heart failure have little to gain from additional treat-
ment with rivaroxaban.
However, for patients with HFrEF, CAD in sinus rhythm with a
recent hospital discharge for worsening heart failure, addition of
rivaroxaban 2.5 mg bd to background anti-platelet therapy did
not improve overall prognosis, although a composite of vascular
outcomes (stroke, myocardial infarction, and sudden death) was
reduced, driven mainly by a reduction in stroke.79,80 This suggests
that for patients with stable CAD and more advanced heart
failure, hospitalizations, and deaths due to worsening heart
failure are not greatly influenced by anti-thrombotic therapy
(Take home figure).
Angiotensin receptor-neprilysin
inhibitors
Heart failure with reduced ejection
fraction
As experience in the implementation of angiotensin receptor-
neprilysin inhibitors (ARNIs) grows, both in clinical trials and in clinic-
al practice, there is a strong argument to consider them as first-line
agents, rather than angiotensin converting-enzyme inhibitors (ACEi)
or angiotensin receptor blockers (ARB), for the treatment of
HFrEF. In PIONEER-HF,81 881 patients with an LVEF <_40% who
were hospitalized for worsening heart failure were randomly
assigned, without a run-in period, to sacubitril/valsartan or enalapril
prior to discharge and followed for 8 weeks to determine the effect
on plasma concentrations of NT-proBNP; about one-third had new-
onset heart failure. Sacubitril-valsartan exerted a greater reduction in
NT-proBNP. Reductions in markers of myocardial injury or stress,
high-sensitivity cardiac troponin-T and soluble ST2, were also
observed. These effects appeared early after randomization (within
1–4 weeks). Moreover, patients assigned to sacubitril/valsartan were
less likely to experience adverse outcomes within the first 8 weeks.
TRANSITION82 randomly assigned 1002 patients to pre- or post-
discharge initiation of sacubitril/valsartan, showing no adverse conse-
quences to earlier administration.
EVALUATE83 compared the effects of sacubitril/valsartan and ena-
lapril on aortic stiffness in HFrEF most of whom were already chron-
ically treated with an ACEi or ARB. After 24 weeks treatment, no
differences in aortic stiffness were observed but slightly greater
reductions in LV end-diastolic and systolic volumes were observed
with sacubitril/valsartan compared with enalapril, although changes in
LVEF were similar. Mitral E-velocity and left atrial volume declined,
consistent with a fall in left atrial pressure. PROVE-HF,84 an observa-
tional study, had similar findings and showed that most of the decline
in NT-proBNP occurred within 14 days consistent with the rapid
onset of clinical benefit observed with sacubitril/valsartan in trials and
clinical practice. PRIME85 was an RCT (n= 118) comparing the effects
of sacubitril/valsartan or valsartan on functional mitral regurgitation in
patients with an LVEF between 25% and 49% who were already
receiving an ACEi or ARB. Those assigned to sacubitril/valsartan had
greater reductions in mitral regurgitation and LV end-diastolic and
left atrial volumes but LVEF increased by a similar small amount in
each group (about 2.5%).
Further reports from PARADIGM-HF suggest that, compared
with enalapril, sacubitril/valsartan may improve markers of collagen
Figure 3 Effect of rivaroxaban 2.5 mg bd and aspirin 100 mg/day compared with aspirin alone for stable CAD, sinus rhythm and heart failure (pre-
dominantly heart failure with preserved ejection fraction) in COMPASS-HF. Reproduced with permission from ref.75
6 J.G.F. Cleland et al.
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..metabolism, in particular, decreasing synthesis of type-I collagen,
which makes an important contribution to myocardial stiffness.86 In I-
PRESERVE, irbesartan (an ARB) did not affect collagen biomarkers
compared with placebo.87
Heart failure with preserved ejection
fraction
PARAGON-HF investigated the effect of sacubitril/valsartan com-
pared to valsartan alone on morbidity and mortality in patients
with HFpEF (defined as an LVEF >45%).88 It was the first RCT since
PEP-CHF89 to require patients to be treated with diuretics, the
first-line treatment for the relief of symptoms and signs of conges-
tion, and to have echocardiographic evidence of cardiac dysfunc-
tion. It was also the first large trial of HFpEF to require all patients
to have raised plasma concentrations of natriuretic peptides, the
most powerful, widely available prognostic marker in HFpEF.
Sacubitril/valsartan was compared with valsartan rather than pla-
cebo because many patients eligible for PARAGON-HF had indica-
tions for ACE inhibitors and ARBs such as hypertension and CAD.
The only trial comparing valsartan to placebo in HFpEF was of
modest size and neutral.90 Previous RCTs of other ARBs, including
candesartan (CHARM-Preserved) and irbesartan (I-PRESERVE)
failed to show substantial benefit for HFpEF.88 Patients had to tol-
erate, sequentially, both valsartan and sacubitril/valsartan at half
the intended target dose before randomization. This simulates clin-
ical practice (doctors do not usually prescribe medicines to
patients unwilling or unable to take them) and reduces the risk of a
neutral trial-outcome due to low adherence. Of 10 539 patients
screened, 4822 were randomized.
PARAGON-HF was neutral for its primary endpoint (CV death or
the total number of recurrent hospitalizations for heart failure91;
Figure 4). Some have argued that the P-value was very close to 0.05
and that it was ‘almost’ positive. This misses the point. The trial shows
that the size of the potential benefit of sacubitril/valsartan for HFpEF
is modest, regardless of the P-value and that the treatment is, overall,
unlikely to be cost-effective. Accordingly, we should look for more
effective treatments or, more controversially, subgroups that obtain
greater benefit. After a median follow-up of 35 months, 23% of
patients experienced a primary event but the annual incidence of CV
and all-cause mortality were, respectively, only about 3% and 5%,
which is similar to those for previous trials of HFpEF and for elderly
patients with resistant hypertension assigned to placebo in HYVET.92
Although <3% of patients were reported to have heart failure in
HYVET, a combination of indapamide and perindopril reduced all-
cause mortality and cut the incidence of heart failure by >50%. Many
of these patients probably had undiagnosed HFpEF prior to random-
ization. Higher rates of hospitalization for heart failure in trials of
HFpEF compared to hypertension may well reflect ascertainment
bias, as clinicians who are interested or expert in the management of
heart failure are more likely to diagnose or report heart failure
events. Overall, these trials suggest that the mortality rate and pos-
sibly the rates of cardiovascular and all-cause hospitalization may be
similar in patients with and without a diagnosis of HFpEF, if they have
a similar burden of co-morbidities. However, it is also likely that
many patients with hypertension, CAD and T2DM have undiagnosed
heart failure.
Subgroup analysis suggested that the effect of sacubitril/valsartan
on the primary endpoint was greater for patients with an LVEF below
the median (57%), but this was driven almost entirely by an effect on
hospitalization for heart failure rather than on CV death.93 The effect
of sacubitril/valsartan on the primary endpoint was also greater for
women and this was true throughout the studied range of LVEF, but
again this was driven by a difference in hospitalization for heart failure
and not CV mortality.94 Reductions in NT-proBNP were similar for
each sex. Sacubitril/valsartan appeared to have a favourable effect on
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Figure 4 Effect of sacubitril/valsartan compared with valsartan for heart failure with preserved ejection fraction in PARAGON-HF. Reproduced
with permission from ref.91
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quality of life for men but not for women. Patients with a recent heart
failure hospitalization may also have benefited more.95 These obser-
vations should be interpreted in the light of a trial that was neutral for
its primary endpoint. No effect was observed on mortality and the
benefits of treatment on quality of life and hospitalizations for heart
failure according to sex were inconsistent. In PARADIGM-HF, no
difference in treatment effect according to sex was observed. A fur-
ther sizeable RCT in HFpEF, PARALLAX-HF, investigating the
effects of sacubitril/valsartan on quality of life and exercise capacity
will provide more evidence in 2020 (https://clinicaltrials.gov/ct2/
show/NCT03066804).
Do women and men respond
differently to treatment?
An analysis of 12 058 patients with HFrEF in two large trials found
that women had more severe symptoms, similar LVEF but a substan-
tially better prognosis than men, even after adjusting for key prognos-
tic variables including aetiology and NT-proBNP (HR: 0.68; 0.62–
0.89).96 A combined analysis of PARAGON-HF and PARADIGM-HF
suggested that patients with HFrEF and HFpEF had similarly impaired
quality of life but that women generally reported a worse quality of
life than men.97 In an observational analysis of patients with HFrEF,
the BIOSTAT survey also found that women generally had a better
prognosis than men despite being prescribed lower doses of beta-
blockers and ACE inhibitors.98 Interestingly, men and women had the
same heart rate, the pharmacodynamic marker of beta-blocker dose.
For patients with HFpEF in the TOPCAT trial, reductions in mortal-
ity, but not hospitalizations for heart failure, were greater for women,
although the interaction was statistically significant only for all-cause
mortality.99 In the PARAGON-HF trial (HFpEF), women obtained
greater benefit than men throughout the studied range of LVEF but
the difference was driven by differences in the rate of hospitalization
for heart failure rather than mortality.94 One obvious difference be-
tween men and women, on average, is size. Cardiac resynchroniza-
tion therapy is reputed to be more effective in women than men, but
differences disappear once adjusted for height.100 Many medicines
are cleared by the kidney. Estimated glomerular filtration rate (eGFR)
is indexed to body surface area (BSA) but doses of treatment are
usually not. A woman (or small man) weighing 64 kg and 160 cm tall
has BSA of 1.67 m2 using the Dubois formula and a man (or large
woman) weighing 85 kg and 180 cm tall has a BSA 2.05 m2. If both
have an eGFR of 60 mL/kg/m2, then the woman (or small man) has an
un-indexed eGFR of 100 mL/min and the man (or large woman) has
an un-indexed eGFR of 123 mL/min. If a medicine is cleared by the
kidney then perhaps smaller people require lower doses to achieve
the same plasma therapeutic concentration and clinical benefit?
Sodium-glucose cotransporter-2
inhibitors
Sodium-glucose cotransporter protein-2 (SGLT2) is found mainly in
the proximal renal tubule and to a lesser extent in other organs.
SGLT1 is abundant in the intestine and myocardium. SGLT2 inhibi-
tors (SGLT2i) cause glycosuria, improving glycaemia, which led to
their development for the treatment of T2DM, and an osmotic diur-
esis, leading to a contraction of plasma volume.101,102 SGLT1 inhibi-
tors reduce intestinal glucose absorption, which can cause diarrhoea
but might have favourable effects on myocardial energy-utilization.103
Most SGLT2i are highly selective, including dapagliflozin and
empagliflozin, but sotagliflozin is less selective.103
EMPA-REG enrolled 7020 patients with T2DM, about 10% of
whom had heart failure (LVEF was not measured) and showed that
empagliflozin reduced the risk of hospitalization for heart failure and
mortality.104 Within a few weeks of initiating empagliflozin, body
weight, and blood pressure fell and haematocrit rose, consistent with
a diuretic effect. Subsequent RCTs of other SGLT2i in T2DM had
similar findings. Meta-analyses suggested that SGLT2i were the hypo-
glycaemic agents most likely to reduce incident heart failure,105–107
whilst observational data raises concerns about insulin therapy.108 A
meta-analysis of RCTs of empagliflozin, canagliflozin, and dapagliflozin
for T2DM, including >30 000 patients, showed benefit, at least for
those with established CV disease.109 For the outcome of hospitaliza-
tion for heart failure or CV death, the annual rate was about 0.6% for
the 13 672 patients with multiple risk factors but without established
CV disease, about 3% for the 20 650 patients with established athero-
sclerotic disease and about 6% for 3891 patients with heart failure at
baseline; the relative risk reductions with SGLT2i in these popula-
tions were 16%, 24%, and 29%, respectively, without evidence of het-
erogeneity amongst agents. The largest of these trials, DECLARE,110
included 17 160 patients of whom 671 had HFrEF and 1316 had
HFpEF or an unspecified LVEF. In a subgroup analysis,111 dapagliflozin
reduced hospitalizations for heart failure and CV mortality for HFrEF
but not for other patient-groups (Figure 5).
DAPA-HF78,112 enrolled 4744 patients and followed them for a
median of 18.3 months, demonstrating that addition of dapagliflozin
to guideline-recommended therapy for HFrEF-reduced hospitaliza-
tions for heart failure by 30% and mortality (mainly cardiovascular)
by 18%, preventing 3–5 hospitalizations and 1–2 deaths per 100
patients treated per year (Figure 6). Patients were somewhat less like-
ly to experience serious adverse events, especially renal, with dapagli-
flozin compared with placebo. The benefits appeared consistent
across subgroups, although patients with evidence of more severe
congestion (worse NYHA class or higher NT-proBNP) may have
received less benefit. Importantly, benefits were similar for those
with and without T2DM and regardless of age.113 Dapagliflozin also
improved quality of life,114 an effect that was confirmed in a smaller
RCT (DEFINE)115 that followed 263 patients for 12 weeks; about
one in six patients got a meaningful benefit, either prevention of wor-
sening or an improvement in symptoms, compared with placebo.
In DAPA-HF, the placebo-corrected decline in weight between
baseline and 8 months was 0.87 kg and this was associated with a
small fall in NT-proBNP and systolic blood pressure and a small in-
crease in haematocrit and serum creatinine. These findings are again
consistent with the belief that SGLT2i exert at least some of their
benefits by enhancing diuresis, either through an osmotic effect of
glycosuria or by interfering with sodium-hydrogen exchange in the
nephron.116 The effects of SGLT2i appear early, consistent with an
immediate haemodynamic effect. However, alternative or additional
explanations for the effect of SGLT2i have been proposed. A small
RCT suggested that empagliflozin stimulated production of erythro-
poietin leading to a rise in haematocrit and a fall in ferritin, a marker
8 J.G.F. Cleland et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz949/5694316 by U
niversity of G
lasgow
 user on 30 January 2020
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
of inflammation and iron deficiency, although not transferrin satur-
ation, a marker of iron deficiency alone.117 However, administration
of exogenous erythropoietin did not reduce morbidity or mortality
in the RED-HF trial.118 Others have suggested that SGLT2i increase
the production of ketones, which may be a more efficient myocardial
energy substrate, or block myocardial sodium–hydrogen exchanger-
3, which may improve myocardial function and reduce fibrosis.119,120
An RCT of empagliflozin in patients with T2DM but not heart fail-
ure121 suggested little effect on cardiac function or remodelling;
RCTs of the effects of SGLT2i on cardiac function in patients with
HFrEF and HFpEF are awaited. Future trials will confirm whether the
benefit observed in DAPA-HF is a class effect and whether they are
effective for HFpEF or when congestion is severe.122,123
Acute heart failure
Two large RCTs of serelaxin failed to confirm the results of the ori-
ginal RELAX-AHF trial. RELAX-AHF-EU,124 an open-label RCT
(n= 2688), reported a similar and low rate for mortality (<_2%) and
re-admissions for heart failure (<1%) at 14 days for patients assigned
placebo or serelaxin, despite a reduction in worsening heart failure at
day 5 [6.7–4.5% (P< 0.008)]. The RELAX-AHF-2 trial,125 a double-
blind RCT (n= 6545), reported that the rates of worsening heart fail-
ure in the first 5 days (about 7%) and 180-day mortality (about 11%)
were similar for placebo and serelaxin. The failure of so many short-
term interventions for AHF may reflect failed therapeutic concepts, in-
effective interventions, or problems with trial design. RCTs of AHF are
Figure 5 Effect of dapagliflozin compared with placebo in type-2 diabetes mellitus in patients with heart failure with reduced ejection fraction,
heart failure with preserved ejection fraction, or without heart failure in DECLARE. Reproduced with permission from ref.111
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..difficult to implement, especially if conducted double-blind. Indeed,
GALACTIC, a trial of personalized, early intensive and sustained
vasodilation with nitrates and hydralazine, also failed to show bene-
fit, calling into question the concept of vasodilator therapy for the
routine management of acute heart failure.126 Many patients pre-
sent with acute breathlessness in the middle of the night. It is diffi-
cult to have research staff available ‘24/7’ when there is no
‘gateway’ similar to a coronary care unit or catheter laboratory.
Compassionate investigators may also be unwilling to enrol frail
elderly patients who are most at risk of adverse outcomes.
Moreover, breathlessness usually responds to oxygen and diuretics
within hours,127 especially for patients with a systolic blood pres-
sure >_125 mmHg, as required in the serelaxin trials. On the other
hand, patients with extensive peripheral oedema,26 renal dysfunc-
tion, and a low blood pressure, who often do not constitute an
acute emergency have a poor prognosis and an unmet need for
more effective interventions; pharmacological, or device.127,128
Stem cell therapy
Intra-myocardial injection of stem cells failed to improve weaning
from left ventricular assist devices.130
Heart failure in patients with
cancer
Interest in cardio-oncology reflects increasing survival after treatment
for cancer, growing awareness of the CV toxicity associated with both
established and new treatments for cancer, and interest in personalized
risk-profiling prior to chemotherapy. People with cardiomyopathy-
related gene mutations may be more prone (7.5% of those with com-
pared to 1.1% of those without a titin gene mutation) to develop ven-
tricular dysfunction after the administration of chemotherapy.131
Interruption of trastuzumab is associated with a higher risk of can-
cer recurrence in women with early invasive HER2þve breast cancer;
about 60% of interruptions are for cardiotoxicity.132 An observation-
al study showed that of 30 women receiving HER2-targeted therapies
who developed an LVEF of 40–49% and were treated prospectively
with beta-blockers and ACE inhibitors, only three went on to de-
velop severe heart failure or a LVEF <35%.133 Cardiac function rarely
returned to normal after completion of treatment, challenging the
view that trastuzumab-related LV dysfunction is usually reversible. A
recent study reported high rates of CV events, especially heart fail-
ure, amongst patients with multiple myeloma receiving potent prote-
asome inhibitors, such as carfilzomib and bortezomib,134 which were
Figure 6 Effect of dapagliflozin compared with placebo in patients with heart failure with reduced ejection fraction, with or without type-2 diabe-
tesmellitus in DAPA-HF. Reproduced with permission from ref.78
10 J.G.F. Cleland et al.
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associated with much poorer survival. Risk factors for developing a
CV event included elevated pre-treatment NT-proBNP or an in-
crease during treatment. A systematic review of prophylactic use
of renin–angiotensin–aldosterone antagonists and beta-blockers
identified 22 relevant RCTs, of which the largest had only 206
patients,135,136 but found no convincing evidence of clinical efficacy
Implementation of therapy
Analyses of administrative data from primary care in the UK suggest
that implementation of therapy has improved substantially over the
last decade, with 72% now prescribed a beta-blocker, although many
patients remain on less than target doses.6 Amongst hospital dis-
charges in England and Wales, 89% of those with HFrEF were dis-
charged on a beta-blocker (https://www.nicor.org.uk/wp-content/
uploads/2019/09/Heart-Failure-2019-Report-final.pdf), which is very
similar to that observed in patients with HFrEF selected for enrolment
in the ESC-EURObservational Heart Failure Long-Term Registry.137
However, an analysis of Medicare beneficiaries in the USA found that
only 51% of patients with HFrEF were prescribed a beta-blocker after
a first or recurrent hospitalization for heart failure and only 12%
received at least >_50% of the target dose by 1 year.138 This suggests
that the organization of care for HFrEF makes an important difference
to treatment and, consequently, outcome. However, a cluster RCT
(n= 2494) of service redesign aiming to improve hospital-to-home
transition, which included self-care education, a structured hospital
discharge summary, family physician follow-up within 1 week, and, for
high-risk patients, home-visits, did not substantially improve patient
well-being or outcome.139 An RCT (n= 110) showed that frequent
(several times per month) visits to participating community pharma-
cies could improve medication adherence and well-being.140 An RCT
of 450 patients found benefits of e-Health intervention on self-care
behaviour and quality of life in the first 3 months after initiation but
not thereafter,141 with no effect on hospitalizations or mortality.
There are many reasons why RCTs of complex interventions fail
including inadequate power, suboptimal trial design, already excellent
or unintended improvements in care for the control group, lack of
long-term engagement and motivation of staff and patients, inclusion
of patients for whom pharmacological intervention is largely ineffect-
ive (e.g. HFpEF) but sometimes we just have to admit that what should
work does not. More evidence is required; learning from past
experience.142
Rehabilitation
Systematic reviews suggest that exercise-based rehabilitation can
improve patients’ well-being and exercise capacity and reduce heart fail-
ure-related and all-cause hospitalization but may not reduce mortality,
despite potentially improving adherence to treatment.143–147 The best
and most cost-effective service-model is a topic of active research.148,149
Palliative care
Morphine relieves chronic breathlessness in patients with chronic
lung disease but data for heart failure are sparse. An RCT of 45
patients failed to demonstrate important clinical benefits of morphine
administration to patients with HFrEF or HFpEF predominantly in
NYHA functional class III.150
Withdrawing treatment for heart
failure after recovery
Withdrawing treatment from patients with idiopathic or genetically
determined dilated cardiomyopathy who have experienced full re-
covery of ventricular function should be done with great caution if at
all.151 Although patients with a recovered LVEF (HFrcEF) may have a
better prognosis, it may still not be good.152 Further research is
required for peripartum and other specific types of cardiomyopathy.
A recent report from an old trial (DIG), suggested that withdrawal of
digoxin was associated with an increased risk of hospitalization for
heart failure but did not affect mortality.153 An RCT of 188 patients
with stable heart failure from Brazil suggested that 75% of patients
could be withdrawn from loop diuretics for at least 90 days without
deterioration in symptoms, need for reinstitution of diuretic therapy,
or a rise in plasma NT-proBNP.154 This is in stark contrast to a
smaller RCT from the UK, where withdrawal of diuretics and other
therapies for 48 h led to a doubling of plasma concentrations of NT-
proBNP, an increase in LV and left atrial volumes and worsening
symptoms.155
Conclusion
Great progress in the understanding and management of heart failure
has been made over the last year. New controversies and new evi-
dence challenge many old assumptions. As ever, some will resist pro-
gress and others will embrace it. You, the reader, must help our
professions and patients find the correct balance between reckless
enthusiasm and diagnostic and therapeutic inertia.
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